Add To Watchlist
Share URL
About The Company
CEO
Mr. Joaquin Duato
Market Cap
356.11 Billion USD
Sector
Healthcare
Website
https://www.jnj.comLast Update
2/22/2024, 12:00:00 PM
Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide.
Read More
Overview
Value
35
Growth
29
Health
50
Management
50
Analyst Opinion
91
Total
47
All Scores Out Of 100
Best Features
- Has a low level of debt
- Has a history of share buybacks
- Low risk of bankruptcy
- Liked by analysts
- Has strong dividend growth
Risk Factors
- Earnings have declined recently
- Does not hold enough liquid assets to cover short term liabilities
- Disliked by Twitter users
- Poor earnings and cashflow growth
- Price-to-earnings ratio of 28.9 is higher than the market average (19.6x)
- High preportion of income is paid as dividend
Market Peers
JNJ
Key Figures
PE Ratio (TTM)
28.88
Margin Of Safety (DCF)
0.41%
Revenue Growth (5 Year Average)
6.34%
Ratings Consensus
Strong Buy
Share Buybacks
0.46%
Dividend Yeild (TTM)
3.01%
Valuation
Value Score
35
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 171.9 USD ✔
Current Price: 162.1 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
28.88x
Free Cashflow Yeild
4.67%
PE/Earnings Growth
N/A
Price/Book
5.68x
Growth
Growth Score
29
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 6.34% is lower than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Earnings growth of -0.04% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 4.24% is lower than the market average (12.35%)
Revenue Growth
6.34%
Earnings Growth
-0.04%
Cashflow Growth
4.24%
Health
Health Score
50
Altman Z Score
4.71
Piostroski Score
8.00
Debt/Equity
0.52x
Current Assets/Liabilities
0.99x
Free Cashflow/Total Debt
0.43x
Debt/Capital
0.72x
Dividend
Secure Dividend Score
65
- ✔ Dividend yeild of 3.01% is more than the market average (1.85%)
- ✔ Dividend is likely safe
- ✔ Dividends have shown growth over the last 5 years
- ✔ Dividend growth has been accelerating recently
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Long term dividend payout ratio of 150.98% is high and may limit growth
- ✘ Payout ratio (TTM) of 83.07% is higher than the average (40%)
Dividend Yeild
3.01%
Dividend Growth
5.89%
Payout Ratio (Earnings)
83.07%
Payout Ratio (Cashflow)
64.50%
Management
Management Score
50
- ✔ Has a history of returning value to shareholders through stock buybacks
- ✔ Return-on-equity of 21.39% is higher than the market average (15%)
- ✘ Return-on-capital-employed of 9.02% is lower than the market average (10%)
- ✘ Has repurchased shares when overvalued
- ✘ Has returned higher dividends when earnings have fallen
Average Buybacks/Dilution
0.46%
Recent Buybacks/Dilution
-8.48%
5 Year Price Volitility
11.38%
Return On Assets
8.77%
Return On Capital Employed
9.02%
Return On Equity
21.39%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
91
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Johnson & Johnson
Currency
USD
Beta
0.540983
Vol Avg
6626913
Ceo
Mr. Joaquin Duato
Cik
0000200406
Cusip
478160104
Exchange
New York Stock Exchange
Full Time Employees
152700
Industry
Drug Manufacturers—General
Sector
Healthcare
Ipo Date
1962-01-02
Address
One Johnson & Johnson Plaza
City
New Brunswick
State
NJ
Country
US
Zip
08933
Phone
732 524 0400
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
27
Twitter Sentiment
0.00
Stocktwits Sentiment
54.00